Duke logo

MEDI4736 and Tremelimumab for Patients with Hepatocellular Carcinoma - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn whether the study drugs Durvalumab, Tremelimumab, and bevacizumab are safe for patients, and whether the study drug regimen can reduce or slow the growth of your cancer.

Additionally, we want to learn what effects, good or bad, the study drugs may have on your body.

What is the Condition Being Studied?

Hepatocellular carcinoma

Who Can Participate in the Study?

Adults who:
- Have never had treatment with drugs similar to durvalumab, tremelimumab, or bevacizumab
- Have a body weight of at least 66 pounds
- Have hepatocellular carcinoma

Age Group
Adults

What is Involved?

If you choose to join this study, you will receive a combination of the study drugs durvalumab and bevacizumab until your cancer gets worse or the study doctor decides to take you off the study.

Study Details

Full Title
A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma
Principal Investigator
Protocol Number
IRB:PRO00066636
NCT:NCT02519348
Phase
Phase II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698